Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
7.87
Nov 13 • 3:59 PM ET Dollar change-0.19 Percentage change(-2.36%)
Aftermarket Close
7.82
Aftermarket • 7:30 PM ET Dollar change-0.05 Percentage change(-0.64%)
Index
-
Market Cap
8.26M
Enterprise Value
1.23M
Income
-14.39M
Sales
0.00M
Book/sh
13.86
Cash/sh
6.95
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
17
IPO
Jun 02, 2016
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.57
P/C
1.13
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.37
Current Ratio
1.37
Debt/Eq
0.02
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-11.90
EPS next Y
-23.40
EPS next Q
-8.87
EPS this Y
88.51%
EPS next Y
64.18%
EPS next 5Y
64.05%
EPS past 3/5Y
57.89% 46.71%
Sales past 3/5Y
- -
EPS Y/Y TTM
85.06%
Sales Y/Y TTM
-
EPS Q/Q
97.18%
Sales Q/Q
-
Insider Own
10.67%
Insider Trans
0.00%
Inst Own
9.23%
Inst Trans
-
ROA
-55.59%
ROE
-1371.64%
ROIC
-78.25%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
1.44%
SMA50
-20.84%
SMA200
-78.33%
Trades
Shs Outstand
1.05M
Shs Float
0.94M
52W High
240.00 -96.72%
52W Low
3.23 143.80%
Volatility
7.54% 13.35%
ATR (14)
0.93
RSI (14)
43.66
Beta
2.08
Rel Volume
0.22
Avg Volume
45.20K
Volume
9,915
Perf Week
-9.54%
Perf Month
6.32%
Perf Quarter
-35.17%
Perf Half Y
-81.35%
Perf YTD
-88.11%
Perf Year
-96.53%
Perf 3Y
-99.82%
Perf 5Y
-99.96%
Perf 10Y
-99.99%
Prev Close
8.06
Price
7.87
Change %
-2.36%
Consensus
Strong Buy
Avg. Price Target
$240.00
Implied Upside
+2,949.6%
Analysts3incl. previous ratings
Rating Distribution2 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 09, 2025Resumed
HH.C. Wainwright
Buy$4-49.2%
Feb 12, 2025Downgrade
MMaxim Group
Buy → Hold
Jul 18, 2022Resumed
OPY logoOOppenheimer
Outperform$14+77.9%
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.
ChairmanMr. Walter V. Klemp
Executive VP & CFOMr. Jonathan P. Foster CPA
Chief Scientific OfficerDr. Donald H. Picker Ph.D.
Co-FounderDr. Waldemar Priebe Ph.D.
Sc.D.Dr. John Paul Waymack M.D.